Diabetes and cancer: therapeutic implications
Abstract
BACKGROUND: The growing coexistence of diabetes and cancer contributes substantially to global morbidity and mortality. Beyond the independent burden of each disease, their intersection introduces unique challenges, particularly in cardiovascular risk. Patients with diabetes, especially those with underlying diabetic cardiomyopathy (DbCM), are at increased risk for cancer therapy-related cardiac dysfunction (CTRCD). Yet, the interplay between DbCM and CTRCD remains underexplored despite clear evidence of overlapping mechanisms and heightened vulnerability in this population. MAIN TEXT: DbCM and CTRCD share key pathophysiologic features, including oxidative stress, mitochondrial dysfunction, inflammation, fibrosis, and impaired calcium handling, which collectively reducing myocardial reserve during cancer therapy. Even in patients without overt DbCM, diabetes management complicates cancer care by influencing treatment tolerance and outcomes. Antidiabetic agents exert pleiotropic effects on both cardiac and oncologic pathways: insulin may worsen remodeling and potentially amplify tumorigenic signaling, whereas metformin and sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrate promise for cardioprotection and modulation of cancer therapy responses. This review synthesizes the current evidence on shared pathobiology, highlights drug-drug interactions that may exacerbate cardiotoxicity and discusses therapeutic opportunities that could improve patient outcomes.…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.